Filing Flows › Orchestra BioMed Holdings (OBIO) › Q3 2025
Orchestra BioMed Holdings (OBIO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Orchestra BioMed Holdings (OBIO) reported revenue of $861K for the third quarter 2025 (Q3 2025), -13% from a year earlier and +3% from the quarter before.
Orchestra BioMed Holdings, Q3 2025: revenue $861K (-13% year over year), net loss $20.8M, operating cash flow −$14.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $861K | +3% | -13% |
| Operating profit | −$20.3M | — | — |
| Net earnings | −$20.8M | — | — |
| Operating cash flow | −$14.6M | — | — |
What changed
Revenue was $861K in Q3 2025, down 13% year over year and up 3% from the previous quarter. Partnership revenue was the largest line at 84% of revenue. Partnership revenue lost $82K year over year (down 10%), 65% of the total change.
Operating costs exceeded revenue by $20.3M, an operating margin of -2359.2%. Total costs grew 22% against a revenue fall of 13%. The fastest-growing cost line was SG&A (+25%). The quarter ended with a net loss of $20.8M, wider than the previous quarter's $19.4M loss.
Operating cash flow was −$14.6M. Non-cash charges added back $81K of depreciation and $3.0M of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $310K exceeded it, leaving free cash flow of −$14.9M.
Questions
What was Orchestra BioMed Holdings' revenue in the third quarter 2025?
Orchestra BioMed Holdings (OBIO) reported revenue of $861K for the third quarter 2025 (Q3 2025), -13% from a year earlier and +3% from the quarter before.